XML 29 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended 9 Months Ended
Oct. 31, 2015
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2017
Significant Accounting Policies [Line Items]            
Common Stock, Par or Stated Value Per Share   $ 0.001 $ 0.001 $ 0.001 $ 0.001  
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount   80,696,070 19,484,667 76,195,921 19,572,040  
Brazil Agreement [Member] | Scenario, Forecast [Member]            
Significant Accounting Policies [Line Items]            
Supply Commitment In Year 2017           $ 24.3
Pfizer Agreement [Member]            
Significant Accounting Policies [Line Items]            
Proceeds From Exchange For Rights To Royalties $ 36.0          
Pfizer Agreement [Member] | Pfizer Incorporation [Member]            
Significant Accounting Policies [Line Items]            
Collaborative Arrangement Revenues and Expenses Sharing Percentage 60.00%          
Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member]            
Significant Accounting Policies [Line Items]            
Collaborative Arrangement Revenues and Expenses Sharing Percentage 40.00%          
Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member]            
Significant Accounting Policies [Line Items]            
Collaborative Arrangement Revenues and Expenses Sharing Percentage 100.00%